Expression Of Vascular Endothelial Growth Factor (VEGF) On Angiofibroma Nasopharyngeal Juvenille At H. Adam Malik Hospital
Expression of Vascular Endothelial Growth Factor (VEGF) on Angiofibroma Nasopharyngeal Juvenille at H. Adam Malik Hospital
Introduction
Angiofibroma Nasopharynx Juvenille (Anj) is a locally aggressive benign tumor that predominantly affects young men. The growth and development of this tumor are influenced by various factors, with Vascular Endothelial Growth Factor (VEGF) playing a crucial role. VEGF is a growth factor closely related to angiogenesis, the process of forming new blood vessels necessary for tumors to obtain nutrients and oxygen. Overexpression of VEGF is often an indicator of tumor progression and is associated with poor prognosis in various types of neoplasms. This study aims to explore and analyze VEGF's expression on the Angiofibroma Nasopharynx Juvenille at H. Adam Malik Hospital.
Research Purposes
The primary objective of this study is to determine the extent of VEGF expression on Angiofibroma Nasopharyngeal Juvenille (ANJ) and identify the factors that affect these expressions, particularly in the context of age and stage of the disease. Understanding the role of VEGF in the progression of Anj is essential for developing effective therapeutic strategies and improving patient prognosis.
Research Methods
This study employed a descriptive method with a cross-sectional cutting study design. Data was collected from the patient's medical records at H. Adam Malik Hospital, Medan, from October 2010 to December 2017. A total of 24 patients were analyzed, with inclusion criteria consisting of a complete medical record, a clear identity, and the presence of paraffin blocks with a diagnosis of Angiofibroma Nasopharyngeal Juvenile.
Research Results
The analysis revealed that 14 people (60.9%) of the total sample, who were male, experienced VEGF overexpression. Notably, 11 people (61.1%) of the 18 individuals under the age of 20 also showed VEGF overexpression. Furthermore, at the Anj stage, it was observed that 90% of patients with stage III experienced VEGF overexpression, whereas in stage IV, this figure increased to 100%.
Discussion
The findings of this study indicate that VEGF overexpression is associated with the severity of Anj's disease. This is in line with previous studies that demonstrate VEGF's role in increasing the density of blood vessels needed by tumors for growth. The significant increase in VEGF expression in patients with advanced stages suggests that VEGF can be an important biomarker for predicting the development of Anj.
The analysis also highlights the importance of monitoring VEGF levels as part of clinical management for AJ patients in H. Adam Malik Hospital. Identification of factors that influence VEGF's expression is expected to help in developing more effective therapeutic strategies and increasing patient prognosis. More aggressive treatment may be needed in patients with VEGF overexpression to control tumor growth and reduce the risk of more serious complications.
Conclusion
This study concluded that there was a significant VEGF overexpression in the Angiofibroma nasopharyngeal Juvenille, especially in an advanced stage. The discovery emphasizes the importance of monitoring VEGF levels as part of clinical management for AJ patients in H. Adam Malik Hospital. The identification of factors that influence VEGF's expression is expected to help in developing more effective therapeutic strategies and increasing patient prognosis.
Implications for Future Research
The findings of this study have significant implications for future research in the field of Anj. Further studies are needed to investigate the role of VEGF in the progression of Anj and to identify potential biomarkers for predicting the development of this disease. Additionally, research is required to develop more effective therapeutic strategies for AJ patients with VEGF overexpression.
Limitations of the Study
This study has several limitations that should be acknowledged. The sample size was relatively small, and the study was conducted at a single hospital. Future studies should aim to recruit a larger sample size and conduct the study at multiple hospitals to increase the generalizability of the findings.
Recommendations for Clinical Practice
The findings of this study have significant implications for clinical practice. Healthcare providers should monitor VEGF levels as part of clinical management for AJ patients in H. Adam Malik Hospital. Additionally, more aggressive treatment may be needed in patients with VEGF overexpression to control tumor growth and reduce the risk of more serious complications.
References
- [List of references cited in the study]
Appendix
- [Appendix containing additional information, such as tables and figures, that support the findings of the study]
Q&A: Expression of Vascular Endothelial Growth Factor (VEGF) on Angiofibroma Nasopharyngeal Juvenille at H. Adam Malik Hospital
Frequently Asked Questions
Q: What is Angiofibroma Nasopharynx Juvenille (Anj)?
A: Angiofibroma Nasopharynx Juvenille (Anj) is a locally aggressive benign tumor that predominantly affects young men. It is a type of tumor that grows in the nasopharynx, which is the upper part of the throat.
Q: What is Vascular Endothelial Growth Factor (VEGF)?
A: Vascular Endothelial Growth Factor (VEGF) is a growth factor that plays a crucial role in angiogenesis, the process of forming new blood vessels. It is essential for the growth and development of tumors, including Anj.
Q: What is the purpose of this study?
A: The primary objective of this study is to determine the extent of VEGF expression on Angiofibroma Nasopharyngeal Juvenille (ANJ) and identify the factors that affect these expressions, particularly in the context of age and stage of the disease.
Q: What were the research methods used in this study?
A: This study employed a descriptive method with a cross-sectional cutting study design. Data was collected from the patient's medical records at H. Adam Malik Hospital, Medan, from October 2010 to December 2017.
Q: What were the results of this study?
A: The analysis revealed that 14 people (60.9%) of the total sample, who were male, experienced VEGF overexpression. Notably, 11 people (61.1%) of the 18 individuals under the age of 20 also showed VEGF overexpression. Furthermore, at the Anj stage, it was observed that 90% of patients with stage III experienced VEGF overexpression, whereas in stage IV, this figure increased to 100%.
Q: What are the implications of this study?
A: The findings of this study have significant implications for clinical practice and future research. Healthcare providers should monitor VEGF levels as part of clinical management for AJ patients in H. Adam Malik Hospital. Additionally, more aggressive treatment may be needed in patients with VEGF overexpression to control tumor growth and reduce the risk of more serious complications.
Q: What are the limitations of this study?
A: This study has several limitations that should be acknowledged. The sample size was relatively small, and the study was conducted at a single hospital. Future studies should aim to recruit a larger sample size and conduct the study at multiple hospitals to increase the generalizability of the findings.
Q: What are the recommendations for clinical practice?
A: The findings of this study have significant implications for clinical practice. Healthcare providers should monitor VEGF levels as part of clinical management for AJ patients in H. Adam Malik Hospital. Additionally, more aggressive treatment may be needed in patients with VEGF overexpression to control tumor growth and reduce the risk of more serious complications.
Q: What are the future directions for research?
A: The findings of this study have significant implications for future research in the field of Anj. Further studies are needed to investigate the role of VEGF in the progression of Anj and to identify potential biomarkers for predicting the development of this disease. Additionally, research is required to develop more effective therapeutic strategies for AJ patients with VEGF overexpression.
Q: How can patients with Anj benefit from this study?
A: Patients with Anj can benefit from this study by being aware of the importance of monitoring VEGF levels as part of clinical management. Additionally, patients with VEGF overexpression may require more aggressive treatment to control tumor growth and reduce the risk of more serious complications.
Q: How can healthcare providers apply the findings of this study to clinical practice?
A: Healthcare providers can apply the findings of this study to clinical practice by monitoring VEGF levels as part of clinical management for AJ patients in H. Adam Malik Hospital. Additionally, healthcare providers should consider more aggressive treatment for patients with VEGF overexpression to control tumor growth and reduce the risk of more serious complications.